Stocks · News reference
Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host Disease
https://www.ema.europa.eu/en/medicines/human/EPAR/ruxolitinib-viatris
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.
8-K filing — Viatris Inc (VTRS)
Filed: 2026-08-06 AccNo: 0001792044-26-000037 Size: 874 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate
Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.60 by 15 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same